EUVIMEDEUVIMED entdecken
Crossref

FDA approves OTC opioid overdose reversal drug

The Brown University Child & Adolescent Psychopharmacology Update · 2026-08 · 28 (8) · 7-8

DOI: 10.1002/cpu.31082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Child & Adolescent Psychopharmacology Update, online erschienen am 29.07.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On June 16, the Food and Drug Administration (FDA) approved over‐the‐counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump's Great American Recovery Initiative , a federal effort to address the U.S. addiction and substance use disorder crisis and coordinate the government's approach to prevention, treatment, and long‐term recovery.

Zitieren

APA

(2026). FDA approves OTC opioid overdose reversal drug. The Brown University Child & Adolescent Psychopharmacology Update, 28(8), 7-8. https://doi.org/10.1002/cpu.31082

Vancouver

FDA approves OTC opioid overdose reversal drug. The Brown University Child & Adolescent Psychopharmacology Update. 2026;28(8):7-8. doi:10.1002/cpu.31082

BibTeX
@article{euvimed2026,
  title = {FDA approves OTC opioid overdose reversal drug},
  journal = {The Brown University Child & Adolescent Psychopharmacology Update},
  year = {2026},
  volume = {28},
  number = {8},
  pages = {7--8},
  doi = {10.1002/cpu.31082}
}
Kostenlos starten →